PBS Changes from 1 April 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1 April 2026.

USANZ Members may be particularly interested in items relating to:

• Intermediate or high risk of recurrence of clear cell variant renal cell carcinoma (RCC) 
  Pembrolizumab (100 mg/4 mL injection, 4 mL vial) (Keytruda®) is now listed on the PBS for the treatment of intermediate or high risk of recurrence of clear cell variant RCC. Prescriptions for treatment are Authority Required (STREAMLINED).
• Urothelial Carcinoma
  Durvalumab (120 mg/2.4 mL injection, 2.4 mL vial; 500 mg/10 mL injection, 10 mL vial) (Imfinzi®) is now listed on the PBS for the treatment of urothelial  carcinoma. Prescriptions for initial and continuing treatments are Authority Required (STREAMLINED).
• Delisting of Diclofenac sodium (100 mg suppository, 20) (Voltaren 100®)

Download the PDF.

This information relates to the administration of these listings by Services Australia. For further information, please download the Frequently Asked Questions. For information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.